A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells

The outlook for patients with refractory/relapsed acute myeloid leukemia (AML) remains poor, with conventional chemotherapeutic treatments often associated with unacceptable toxicities, including severe infections due to profound myelosuppression. Thus there exists an urgent need for more effective...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Adv
Asıl Yazarlar: Kovtun, Yelena, Jones, Gregory E., Adams, Sharlene, Harvey, Lauren, Audette, Charlene A., Wilhelm, Alan, Bai, Chen, Rui, Lingyun, Laleau, Rassol, Liu, Fenghua, Ab, Olga, Setiady, Yulius, Yoder, Nicholas C., Goldmacher, Victor S., Chari, Ravi V. J., Pinkas, Jan, Chittenden, Thomas
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2018
Konular:
Myeloid Neoplasia
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5916008/
https://ncbi.nlm.nih.gov/pubmed/29661755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018017517
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller